Skip to Main Content

In a long-awaited move, an independent advisory panel is recommending that doctors be encouraged to offer an HIV prevention pill, a step that would quickly expand insurance coverage for a medicine that has been difficult for some people to access due to its cost.

In explaining its decision, the U.S. Preventive Services Task Force determined there is “high certainty” that using the pill would provide a “substantial” benefit for people at a high risk of becoming infected with HIV, the virus that leads to AIDS. The independent panel of experts noted that it found “adequate epidemiologic data” on risk factors that can be used to identify people who are at a high risk of acquiring HIV.


Should physicians adopt the recommendation, the medicine may finally fill its potential. Known as PrEP but sold commercially as Truvada by Gilead Sciences (GILD), the pill was approved to treat HIV in 2004, and then endorsed for prevention in 2012. Yet the panel noted that an estimated 1.1 million people in the U.S. are currently living with HIV.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.